MET and lung adenocarcinoma: ,14, 15, 16 Furthermore, a case report demonstrated the effectiveness of erlotinib plus crizotinib in a patient with lung adenocarcinoma harboring concurrent de novo EGFR L858R and MET amplification (FISH MET/centromere of chromosome 7 ratio >15).11